Meda Aktiebolag summons noteholders’ meetings

Meda Aktiebolag summons noteholders’ meetings for the purposes of approving the insertion of an early redemption call option into the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme

Mylan N.V., the parent of the Company, is consolidating debt in acquired entities to Mylan N.V. in order to optimise its overall debt profile. Therefore, today, Meda Aktiebolag (the “ Company ”) has summoned noteholders’ meetings to take place on 6 December 2017 at 09:00 hours (CET) and 09:30 hours (CET) respectively in respect of the:

(i) SE0005132180 – STIBOR 3M +2.85% 2013/2018 notes (the “ 2018 Notes ”); and
(ii) SE0005991635 – STIBOR 3M +1.65% 2014/2019 notes (the “ 2019 Notes ” and together, with the 2018 Notes, the “ Notes ”),

issued under the SEK 7,000,000,000 medium term notes programme of the Company originally established on 25 May 2012 (as updated on 31 July 2012, 12 May 2014 and 16 July 2015), for the purposes of approving an amendment to the terms and conditions of the Notes to insert an early redemption call option (the “ Call Option ”). The Company intends to exercise the relevant Call Option to redeem the Notes in full thereafter.

As further described in the summons to the meetings, holders of the outstanding notes will, subject to the approval of the amendment of the terms and conditions and the Company’s consequent exercise of the Call Option, receive a redemption price per Note as set out below, together with accrued but unpaid interest up to (and including) the relevant redemption date. Subject to the approval of the amendment of the relevant terms and conditions, holders of the Notes may be eligible to receive an early consent fee as set out below if the holders vote in favour of the amendment to the relevant terms and conditions by no later than 17:30 (CET) 29 November 2017.

Early Consent Fee
(as a percentage of the nominal amount of each note)
Redemption price per Note
(as a percentage of the nominal amount of each note)
2018 Notes 0.15 100.710
2019 Notes 0.50 101.625

For a complete description of the proposed amendment to the relevant terms and conditions, the relevant voting procedures and other information relating to the meetings, please refer to the relevant summons which can be obtained via Skandinaviska Enskilda Banken AB (publ) acting as Tabulation and Paying Agent.

The Tabulation and Paying Agent:

Skandinaviska Enskilda Banken AB (publ)
Stjärntorget 4
SE-106 40 Stockholm
Sweden
Tel: +46 (0)8 763 80 96
Email: sebtenderagent@seb.se
Attention: SEB Tender Agent

The Solicitation Agent is:

Skandinaviska Enskilda Banken AB (publ)
Kungsträdgårdsgatan 8
SE-106 40 Stockholm
Sweden
Tel: +46 (0)8 506 232 21

Solna, 7 November 2017

The Board of directors

Meda Aktiebolag

For further inquiries, please contact:
Melissa Trombetta, Head of Global Investor Relations, Mylan NV.
tel: +1 (917) 262-2958
Melissa.Trombetta@mylan.com

This is information that Meda Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:00 a.m. CET on 7 November 2017.

Meda Aktiebolag is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in close to 60 countries. Find out more, visit www.meda.se .

Tags:

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Subscribe

Documents & Links